Functional Validation of a Multispecific T-cell Engager in Acute Myeloid Leukemia Using Patient-Derived Samples

Background

The development of multispecific T-cell engagers (TCEs) represents a promising strategy in hematologic malignancies, particularly in acute myeloid leukemia (AML). These molecules aim to redirect T-cell cytotoxicity toward leukemic blasts while sparing normal hematopoietic stem and progenitor cells. Despite encouraging preclinical concepts, demonstrating both efficacy and safety in translational models remains a major challenge prior to clinical entry.

Study Objective

A clinical-stage biopharmaceutical company required functional validation of a novel multispecific TCE for AML. The therapeutic candidate was designed to recognize several AML-associated antigens simultaneously and to engage CD3 for T-cell activation. The central objectives were to establish ex vivo efficacy in primary AML samples, to confirm selectivity against malignant versus healthy cells, and to evaluate the risk of cytokine-related toxicity.

Methods

Vivia Biotech applied its proprietary ex vivo native environment assays, a form of New Approach Methodology (NAM) that preserves the complexity of patient-derived samples. The study design included:

Functional assays on fresh and cryopreserved bone marrow and peripheral blood samples from AML patients with characterized molecular backgrounds
Flow cytometry to quantify target antigen expression and to monitor cell viability, apoptosis, and T-cell activation
Multiparametric assessment of cytokine release in whole blood and AML patient samples following exposure to the TCE

This methodological approach enabled the evaluation of both efficacy and safety within a human-relevant biological context.

Results

The data demonstrated robust and selective activity of the multispecific TCE in patient-derived AML blasts:

The functional readouts confirmed the intended mechanism of action and provided a high degree of translational confidence for further clinical development.

Impact

The ex vivo evidence generated by this study had several important implications:

The findings supported advancement of the candidate into a phase 1 dose-escalation trial
Results were incorporated into a peer-reviewed publication, strengthening the scientific foundation of the program
The translational validation offered by ex vivo NAMs was recognized as a decisive factor in regulatory interactions and in internal decision-making for the client

Conclusion

This case study illustrates how ex vivo assays in patient-derived samples function as predictive NAMs that directly align with current FDA guidance on preclinical development. By generating functional human data early, they reduce reliance on animal models, de-risk first-in-human trials, and support accelerated timelines.

For novel immunotherapies such as multispecific T-cell engagers in AML, the use of patient-derived ex vivo platforms provides the rigorous scientific evidence required to move confidently from preclinical discovery to clinical evaluation.